ADVERTISEMENT

Conference Report

ASCO 2022 – Testing conjugates as a novel approach to heavily pretreated advanced breast cancer

Cristina Ferrario — Agenzia Zoe   |   06 June 2022

Takeaway

  • In patients with heavily pre-treated HR+/HER2- advanced breast cancer with disease progression following endocrine-based therapy, sacituzumab govitecan improved progression-free survival (PFS) by 34% compared with standard chemotherapy.
  • No new safety signals emerged.
  • The antibody-drug conjugate sacituzumab govitecan should be considered a potential treatment option for these patients.

Why this...

          

November Challenge

Ends in 1d 6h
left
right

Topic Challenges

left
right